ABSTRACT

Introduction: As a novel glucagon-like peptide-1receptor agonist (GLP-1 RA) for type 2 diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been assessed in several country settings. The authors’ objective was to systematically review the existing pharmacoeconomic literature evaluating the cost-effectiveness associated with once-weekly semaglutide compared with other GLP-1 RAs and provide implications for further researches.

Areas covered: We conducted a systematic literature review of cost-effectiveness analysis (CEA) published up to 25 July 2020 in PubMed, web of science, and the ISPOR presentation database, compared once-weekly semaglutide with other GLP-1 RAs in T2D. Nineteen studies were identified, including 8 short-term and 11 long-term studies. General characteristics and main results of the included studies were summarized.

Expert opinion: This review provided references for other countries to overview the value of once-weekly semaglutide compared with other GLP-1 RAs in T2D in the healthcare decision-making process and to conduct their CEA studies associated with once-weekly semaglutide. The authors found that the cardiovascular (CV) benefit of once-weekly semaglutide was under-estimated in current studies and suggested that the methods of economic evaluations for novel anti-diabetic drugs with CV benefit should be improved in future researches.

摘要

简介：作为用于治疗2型糖尿病（T2D）的新型胰高血糖素样肽-1受体激动剂（GLP-1 RA），已经在多个国家/地区评估了每周一次的semaglutide的经济价值。作者的目的是系统地回顾现有的药物经济学文献，以评估与其他GLP-1 RA相比每周一次的semaglutide的成本效益，并为进一步的研究提供启示。

涵盖的领域：我们对截至2020年7月25日在PubMed，科学网络和ISPOR演示数据库中发布的成本效益分析（CEA）进行了系统的文献综述，将每周一次的semaglutide与其他T2D中的GLP-1 RA进行了比较。确定了19项研究，包括8项短期研究和11项长期研究。总结了纳入研究的一般特征和主要结果。

专家意见：这篇评论为其他国家提供了参考，以概述在医疗保健决策过程中每周一次塞马鲁肽与其他GLP-1 RA在T2D中的价值，并进行与每周一次塞马鲁肽相关的CEA研究。作者发现，在当前研究中，每周一次的semaglutide对心血管（CV）的益处被低估了，并建议在未来的研究中应改进对具有CV益处的新型抗糖尿病药物进行经济评估的方法。